Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. - Wikidata - awgldk - TriplyDB

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.

http://www.wikidata.org/entity/Q33285468

about

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells Imatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cells Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.A dual-fluorescence high-throughput cell line system for probing multidrug resistance.Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib Defects in innate immunity render breast cancer initiating cells permissive to oncolytic adenovirus.Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity.Development and targeted use of nilotinib in chronic myeloid leukemia.Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.The challenge of exploiting ABCG2 in the clinic.ABCG2: a perspective.Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters.Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia.Photochemical internalisation, a minimally invasive strategy for light-controlled endosomal escape of cancer stem cell-targeting therapeutics.Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models Activation of abl family kinases in solid tumors.Cancer stem cells and chemoresistance: The smartest survives the raid BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.Sequence mutations of the substrate binding pocket of stem cell factor and multidrug resistance protein ABCG2 in renal cell cancer: a possible link to treatment resistance Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges.Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia.Reversing multidrug resistance by tyrosine kinase inhibitors Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design.Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.

P2860

Q26781539-925DB734-B556-4074-893C-01F386889D0B Q26849792-FC22504C-6661-44FE-A990-D8A75113AF79 Q26865927-753F3176-7682-46ED-8EC8-BE016E944AD7 Q28081844-605C8981-05C7-405C-A8A0-5D0DBBBCEFBF Q28475378-A97917DF-7CB4-4B3D-ACB6-4C1CC08CA2A8 Q28477903-3EA8DB38-1B9B-4467-AB0D-841EEC661702 Q28481327-8BF67157-3DBB-4685-A406-1746BB0CA008 Q28484493-270DE49F-1F61-40AE-A2DB-1B069CE2D0BC Q33410206-F7558C61-400D-46B5-BA56-076B6A27B8D2 Q33472881-9F54A670-78B3-4214-96F0-D96CA2D8F791 Q33561227-CF16C97E-9F73-45BB-9CA8-432ED2CCA3A9 Q33566582-336364E5-E011-4F65-B22F-E1543DF5F975 Q33707394-520F373F-02DC-476A-B3C5-B50992036298 Q33747762-A9261522-4AF2-4AF1-88D9-60DFD58676D3 Q34130343-56597CB7-9DF2-495A-B113-665B0A39B4DE Q34233691-BBAE7A71-86EE-4FE6-A447-5D2D6D8F92DA Q34613968-BD781FF0-9162-4FDC-8951-998793F3D651 Q34871636-06FBABAA-CEB2-4169-89E7-67D5125D94EA Q34968909-3C664437-5492-43EB-BA28-11D0F03604C5 Q35016817-5B4A2C96-4E0C-4C69-8170-C20747828837 Q35141800-F8F90A03-E6FB-416C-96A8-5303114A66A0 Q35186322-A8E68CD9-D44B-4A92-9216-492C71C077F1 Q35585820-64BF47EF-DF8A-4492-976D-24A858689A62 Q35708124-82D6C64E-64F2-4AE9-8A8C-24CA05C6D0C5 Q35773205-C4626599-29F2-4BC1-94DE-9663AB5FBE5B Q35946822-4EB06A33-3369-4888-B156-119E218DE27D Q36442931-BF1487E6-6CCC-4A1E-B72F-DDB6260B2538 Q36443421-3FA56FC2-93B8-4AC9-B941-A1AC68B3A359 Q36730432-254FF7E6-8FED-4A46-9966-B0076D33602E Q36732681-09D2C695-B8B3-4ED8-9FBC-4890BF8EB3BE Q36858592-26C0B92F-9FC8-4EA3-AC49-B5D363A0FA74 Q37076348-57C8F3D8-E4F0-4CEF-805F-294A9F7218E6 Q37078093-E6AE3443-45A0-429B-9F4E-D4F4C00539FD Q37109225-BDF181EF-89F4-4976-95F0-91E9F771DFB8 Q37132845-DA9D6335-3FEC-4C6D-8E97-5E66AAE99057 Q37183670-04299DD3-05B4-4C70-947E-4D8506261D30 Q37187988-CFC35DA6-3E4C-48C3-866E-0D7EC5747B5C Q37188016-DFE2D1E0-D218-4B43-81FE-902A54570A86 Q37219909-07B21795-3BC3-4909-A116-46EA88736AD3 Q37310478-1D8436FF-6D9D-4FF6-99C0-06CFD051C925

P2860

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.

http://www.wikidata.org/entity/Q33285468

description

2007 nî lūn-bûn

@nan

2007 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մարտին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Imatinib mesylate and nilotini ...... tive hematopoietic stem cells.

@ast

Imatinib mesylate and nilotini ...... tive hematopoietic stem cells.

@en

type

label

Imatinib mesylate and nilotini ...... tive hematopoietic stem cells.

@ast

Imatinib mesylate and nilotini ...... tive hematopoietic stem cells.

@en

prefLabel

Imatinib mesylate and nilotini ...... tive hematopoietic stem cells.

@ast

Imatinib mesylate and nilotini ...... tive hematopoietic stem cells.

@en

P1433

Q33285468-A6092BE8-9CB4-42DD-AAF9-4FDC75D779D1

P1476

Q33285468-4A1D8A57-6934-4309-9F0A-26B0EA529637

P2093

Q33285468-0C4D5BE9-BA5C-480D-9CAE-140B043ACA80

Q33285468-1C73AF2E-57C8-4C23-8321-8D3B0D4D0484

Q33285468-2FAAE155-ABA8-4461-83F2-76D6435F2448

Q33285468-3C0E3983-6FAA-43FE-BA70-560C9383A7E6

Q33285468-44706E0E-A4A1-4567-B490-0C604ABAA426

Q33285468-C0554DB5-4A9A-4493-933B-918C63838AB1

Q33285468-D6AFFA93-2B3E-426D-BCE0-FFCC578CAFCB

Q33285468-EEFEA229-14AB-461F-910E-656A3A3E9D8B

Q33285468-F4BA4381-CC8E-4928-8DD3-79C56C8A7196

Q33285468-F70F1CDB-B578-4987-9756-367D124F0F30

P2860

Q33285468-01606807-13B6-4C5A-9962-08B866ADCFF4

Q33285468-117B15F5-3B0F-41E4-8BAF-B31317D3C229

Q33285468-29946CDC-71C9-4089-B3B8-5C0D9F251ADF

Q33285468-31A493BE-62B6-47C2-8D6C-4352ADD035A1

Q33285468-31DA22F8-2F00-4AF9-9805-27FD28396B22

Q33285468-3523C271-9051-496B-A8E3-3D2601715D6A

Q33285468-3F8C698B-D656-4430-B37C-8DA9D0216C0C

Q33285468-4243C1F9-DE99-4383-9686-3A80E1751EF0

Q33285468-44717347-0629-4BFD-8D36-5A9E8490E223

Q33285468-4562FDB7-74CD-4365-91B7-E6C526FEB49F

P2888

Q33285468-37FFF328-DCE2-4D12-95C4-4A5F7BFD28E6

P304

Q33285468-95740998-1AF3-4537-A336-07F327A303F3

P31

Q33285468-B5C6DDCD-5908-4A51-82AC-D787130170D8

P356

Q33285468-8C271FDC-4C81-416D-9B7E-476F227772D3

P433

Q33285468-3BEB0F29-2059-4494-B359-3EAD6030C809

P478

Q33285468-535DB36D-0E52-4A0E-B999-D13CFD12F70C

P50

Q33285468-A67F8C1D-1F4D-410F-8A66-3D77CD7233E9

Q33285468-CBF272DF-20B1-4540-8612-3C4D91D8BA1A

P577

Q33285468-3A7FBC11-5939-4B67-83E6-029DF86EBCA3

P5875

Q33285468-C24CF9CE-FB3B-4FDE-B781-4E4046355A8E

P6179

Q33285468-83F2FA5A-D562-412D-ACD9-7F67066F4007

P698

Q33285468-600366B9-A30D-46D9-9BF5-EB52315FE1BD

P356

P1433

P1476

Imatinib mesylate and nilotini ...... itive hematopoietic stem cells

@en

P2093

A Burchert

http://www.w3.org/2001/XMLSchema#string

A Neubauer

http://www.w3.org/2001/XMLSchema#string

C Brendel

http://www.w3.org/2001/XMLSchema#string

C Scharenberg

http://www.w3.org/2001/XMLSchema#string

M Dohse

http://www.w3.org/2001/XMLSchema#string

S E Bates

http://www.w3.org/2001/XMLSchema#string

S Shukla

http://www.w3.org/2001/XMLSchema#string

S V Ambudkar

http://www.w3.org/2001/XMLSchema#string

U Boudriot

http://www.w3.org/2001/XMLSchema#string

Y Wang

http://www.w3.org/2001/XMLSchema#string

P2860

The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo

Akt signaling regulates side population cell phenotype via Bcrp1 translocation.

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

P2888

P304

1267-1275

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.LEU.2404638

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6312703

http://www.w3.org/2001/XMLSchema#string

P6179

1025136515

http://www.w3.org/2001/XMLSchema#string

P698

17519960

http://www.w3.org/2001/XMLSchema#string